195 related articles for article (PubMed ID: 25326286)
1. Inhibition of human aldehyde oxidase activity by diet-derived constituents: structural influence, enzyme-ligand interactions, and clinical relevance.
Barr JT; Jones JP; Oberlies NH; Paine MF
Drug Metab Dispos; 2015 Jan; 43(1):34-41. PubMed ID: 25326286
[TBL] [Abstract][Full Text] [Related]
2. Effect of tea beverages on aldehyde oxidase activity.
Tayama Y; Sugihara K; Sanoh S; Miyake K; Morita S; Kitamura S; Ohta S
Drug Metab Pharmacokinet; 2011; 26(1):94-101. PubMed ID: 21084768
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in silico studies to explore structural features of flavonoids for aldehyde oxidase inhibition.
Hamzeh-Mivehroud M; Rahmani S; Feizi MA; Dastmalchi S; Rashidi MR
Arch Pharm (Weinheim); 2014 Oct; 347(10):738-47. PubMed ID: 24956178
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of guinea pig aldehyde oxidase activity by different flavonoid compounds: An in vitro study.
Siah M; Farzaei MH; Ashrafi-Kooshk MR; Adibi H; Arab SS; Rashidi MR; Khodarahmi R
Bioorg Chem; 2016 Feb; 64():74-84. PubMed ID: 26722818
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of xanthine oxidase by the aldehyde oxidase inhibitor raloxifene: implications for identifying molybdopterin nitrite reductases.
Weidert ER; Schoenborn SO; Cantu-Medellin N; Choughule KV; Jones JP; Kelley EE
Nitric Oxide; 2014 Feb; 37():41-5. PubMed ID: 24406683
[TBL] [Abstract][Full Text] [Related]
6. Identification of a suitable and selective inhibitor towards aldehyde oxidase catalyzed reactions.
Nirogi R; Kandikere V; Palacharla RC; Bhyrapuneni G; Kanamarlapudi VB; Ponnamaneni RK; Manoharan AK
Xenobiotica; 2014 Mar; 44(3):197-204. PubMed ID: 24156774
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the Disposition of a Mixed Aldehyde Oxidase/Cytochrome P450 Substrate in Rats with Attenuated P450 Activity.
Crouch RD; Morrison RD; Byers FW; Lindsley CW; Emmitte KA; Daniels JS
Drug Metab Dispos; 2016 Aug; 44(8):1296-303. PubMed ID: 26936972
[TBL] [Abstract][Full Text] [Related]
8. Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.
Barr JT; Jones JP
Drug Metab Dispos; 2013 Jan; 41(1):24-9. PubMed ID: 22996261
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Inhibition of Human Aldehyde Oxidase Activity by Clinically Relevant Concentrations of Gefitinib and Erlotinib: Comparison with Select Metabolites, Molecular Docking Analysis, and Impact on Hepatic Metabolism of Zaleplon and Methotrexate.
Tan WK; Tan ARY; Sivanandam P; Goh EJH; Yap ZP; Saburulla NF; Austin-Muttitt K; Mullins JGL; Lau AJ
J Pharmacol Exp Ther; 2020 Aug; 374(2):295-307. PubMed ID: 32393528
[TBL] [Abstract][Full Text] [Related]
10. Aldehyde oxidase and its role as a drug metabolizing enzyme.
Dalvie D; Di L
Pharmacol Ther; 2019 Sep; 201():137-180. PubMed ID: 31128989
[TBL] [Abstract][Full Text] [Related]
11. Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation.
Gufford BT; Chen G; Lazarus P; Graf TN; Oberlies NH; Paine MF
Drug Metab Dispos; 2014 Oct; 42(10):1675-83. PubMed ID: 25008344
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions.
Barr JT; Jones JP
Drug Metab Dispos; 2011 Dec; 39(12):2381-6. PubMed ID: 21940905
[TBL] [Abstract][Full Text] [Related]
13. Enzyme Kinetics, Pharmacokinetics, and Inhibition of Aldehyde Oxidase.
Paragas EM; Choughule K; Jones JP; Barr JT
Methods Mol Biol; 2021; 2342():257-284. PubMed ID: 34272698
[TBL] [Abstract][Full Text] [Related]
14. Structure-based investigation of rat aldehyde oxidase inhibition by flavonoids.
Hamzeh-Mivehroud M; Rahmani S; Rashidi MR; Hosseinpour Feizi MA; Dastmalchi S
Xenobiotica; 2013 Aug; 43(8):661-70. PubMed ID: 23282065
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Carbazeran 4-Oxidation and
Xie J; Saburulla NF; Chen S; Wong SY; Yap ZP; Zhang LH; Lau AJ
Drug Metab Dispos; 2019 Jan; 47(1):26-37. PubMed ID: 30337443
[TBL] [Abstract][Full Text] [Related]
16. Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase.
Coelho C; Foti A; Hartmann T; Santos-Silva T; Leimkühler S; Romão MJ
Nat Chem Biol; 2015 Oct; 11(10):779-83. PubMed ID: 26322824
[TBL] [Abstract][Full Text] [Related]
17. Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes.
Hutzler JM; Yang YS; Albaugh D; Fullenwider CL; Schmenk J; Fisher MB
Drug Metab Dispos; 2012 Feb; 40(2):267-75. PubMed ID: 22031625
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug-drug interactions.
Takaoka N; Sanoh S; Okuda K; Kotake Y; Sugahara G; Yanagi A; Ishida Y; Tateno C; Tayama Y; Sugihara K; Kitamura S; Kurosaki M; Terao M; Garattini E; Ohta S
Biochem Pharmacol; 2018 Aug; 154():28-38. PubMed ID: 29678521
[TBL] [Abstract][Full Text] [Related]
19. Species-Specific Involvement of Aldehyde Oxidase and Xanthine Oxidase in the Metabolism of the Pyrimidine-Containing mGlu
Crouch RD; Blobaum AL; Felts AS; Conn PJ; Lindsley CW
Drug Metab Dispos; 2017 Dec; 45(12):1245-1259. PubMed ID: 28939686
[TBL] [Abstract][Full Text] [Related]
20. Case Study 11: Considerations for Enzyme Mapping Experiments-Interaction Between the Aldehyde Oxidase Inhibitor Hydralazine and Glutathione.
Crouch RD; Beers JL; Jackson KD
Methods Mol Biol; 2021; 2342():809-823. PubMed ID: 34272718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
